Kylie Grainger, PhD
Chemist, Division of Post-Marketing Activities II, Office of Lifecycle Drug Products, OPQ, CDER
Dr. Kylie Grainger is a chemist in the Division of Post-Marketing Activities II (DPMA II), Office of Lifecycle Drug Products (OLDP) within the Office of Pharmaceutical Quality (OPQ). DPMA II is responsible for monitoring the lifecycle of generic drug products through the collaborative evaluation and assessment of supplements and annual reports using risk management practices. Dr. Grainger joined the FDA in in 2014. Prior to joining FDA, she completed post-doctoral studies at the University of Maryland School of Pharmacy. She earned a Ph.D. in Chemistry from Northwestern University and a B.S. in Chemistry from Furman University.